Svenja Kopelke1,2, Troels W Kjaer3, Soeren Tvilsted4, Steven E Schild5, Tobias Bartscht2, Dirk Rades6. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Department of Hematology and Oncology, University of Lübeck, Lübeck, Germany. 3. Department of Neurology, Zealand University Hospital, Roskilde, Denmark. 4. Research Projects and Clinical Optimization, Zealand University Hospital, Koege, Denmark. 5. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 6. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; dirk.rades@uksh.de.
Abstract
BACKGROUND/AIM: Many patients with malignant gliomas are scheduled for radiochemotherapy, which may cause emotional distress associated with sleep problems. This study aimed to determine the prevalence of such sleep problems in these patients and identify risk factors. PATIENTS AND METHODS: Fifty-seven patients scheduled for radiochemotherapy for grade II-IV gliomas were retrospectively investigated for pre-treatment sleep problems. Fifteen characteristics were evaluated including temporal relation to COVID-19 pandemic, age, gender, performance status, comorbidity, (family) history of malignancies, distress score, emotional problems, physical problems, practical problems, involved sites, glioma grade, upfront surgery, and corticosteroids. RESULTS: Nineteen patients stated pre-treatment sleep problems (prevalence=66.7%). Significant associations with sleep problems were found for female gender (p=0.023), presence of emotional problems (p=0.006), and ≥4 physical problems (p<0.001). A trend was found for distress scores ≥5 (p=0.077). CONCLUSION: The prevalence of sleep problems was high. Risk factors were determined that can be used to identify patients who likely benefit from psychological support.
BACKGROUND/AIM: Many patients with malignant gliomas are scheduled for radiochemotherapy, which may cause emotional distress associated with sleep problems. This study aimed to determine the prevalence of such sleep problems in these patients and identify risk factors. PATIENTS AND METHODS: Fifty-seven patients scheduled for radiochemotherapy for grade II-IV gliomas were retrospectively investigated for pre-treatment sleep problems. Fifteen characteristics were evaluated including temporal relation to COVID-19 pandemic, age, gender, performance status, comorbidity, (family) history of malignancies, distress score, emotional problems, physical problems, practical problems, involved sites, glioma grade, upfront surgery, and corticosteroids. RESULTS: Nineteen patients stated pre-treatment sleep problems (prevalence=66.7%). Significant associations with sleep problems were found for female gender (p=0.023), presence of emotional problems (p=0.006), and ≥4 physical problems (p<0.001). A trend was found for distress scores ≥5 (p=0.077). CONCLUSION: The prevalence of sleep problems was high. Risk factors were determined that can be used to identify patients who likely benefit from psychological support.
Authors: Jimmie C Holland; Barbara Andersen; William S Breitbart; Luke O Buchmann; Bruce Compas; Teresa L Deshields; Moreen M Dudley; Stewart Fleishman; Caryl D Fulcher; Donna B Greenberg; Carl B Greiner; George F Handzo; Laura Hoofring; Charles Hoover; Paul B Jacobsen; Elizabeth Kvale; Michael H Levy; Matthew J Loscalzo; Randi McAllister-Black; Karen Y Mechanic; Oxana Palesh; Janice P Pazar; Michelle B Riba; Kristin Roper; Alan D Valentine; Lynne I Wagner; Michael A Zevon; Nicole R McMillian; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2013-02-01 Impact factor: 11.908
Authors: ZoltÁn VÉgvÁry; Barbara DarÁzs; Viktor Paczona; Ágnes Dobi; Zita Reisz; ZoltÁn Varga; Emese Fodor; Adrienn CserhÁti; Judit OlÁh; DÁvid Kis; PÁl BarzÓ; Katalin HideghÉty Journal: Anticancer Res Date: 2020-08 Impact factor: 2.480
Authors: Marthe C M Peeters; Linda Dirven; Johan A F Koekkoek; Ellen G Gortmaker; Lara Fritz; Maaike J Vos; Martin J B Taphoorn Journal: J Neurooncol Date: 2020-01-01 Impact factor: 4.130